Synthesis of a series of NAD+ analogues, potential inhibitors of PARP 1, using ADP conjugates functionalized at the terminal phosphate group
- Authors: Sherstyuk Y.V.1, Zakharenko A.L.1, Kutuzov M.M.1, Sukhanova M.V.1,2, Lavrik O.I.1,2, Silnikov V.N.1, Abramova T.V.1
-
Affiliations:
- Institute of Chemical Biology and Fundamental Medicine
- Novosibirsk State University
- Issue: Vol 43, No 1 (2017)
- Pages: 76-83
- Section: Article
- URL: https://journals.rcsi.science/1068-1620/article/view/228420
- DOI: https://doi.org/10.1134/S1068162017010095
- ID: 228420
Cite item
Abstract
A convenient approach has been proposed to the synthesis of nicotinamide adenine dinucleotide (NAD+) mimetics, which comprise morpholino analogues of nucleosides. The approach is based on the use of ADP conjugates containing an amino group, which is tethered to the terminal phosphate through the aliphatic linker by the phosphodiester bond. We have synthesized four series of the NAD+ mimetics, which differ in the type of the modified nucleoside (2-aminomethylmorpholine (Mor) or 2-aminomethyl-4-carboxymethylmorpholine (MorGly) derivatives), in the linker length, and in the manner of the nucleoside attachment to the ADP derivative. We have studied the efficiency of NAD+ mimetics in the inhibition of the auto-poly(ADP-ribosyl)ation by the PARP 1 enzyme. The linker length, the mode of the attachment of the morpholino nucleoside analogue, and the nature of the heterocyclic base of the modified nucleoside were shown to inf luence the inhibition efficiency.
About the authors
Yu. V. Sherstyuk
Institute of Chemical Biology and Fundamental Medicine
Email: abramova@niboch.nsc.ru
Russian Federation, Novosibirsk, 630090
A. L. Zakharenko
Institute of Chemical Biology and Fundamental Medicine
Email: abramova@niboch.nsc.ru
Russian Federation, Novosibirsk, 630090
M. M. Kutuzov
Institute of Chemical Biology and Fundamental Medicine
Email: abramova@niboch.nsc.ru
Russian Federation, Novosibirsk, 630090
M. V. Sukhanova
Institute of Chemical Biology and Fundamental Medicine; Novosibirsk State University
Email: abramova@niboch.nsc.ru
Russian Federation, Novosibirsk, 630090; Novosibirsk, 630090
O. I. Lavrik
Institute of Chemical Biology and Fundamental Medicine; Novosibirsk State University
Email: abramova@niboch.nsc.ru
Russian Federation, Novosibirsk, 630090; Novosibirsk, 630090
V. N. Silnikov
Institute of Chemical Biology and Fundamental Medicine
Email: abramova@niboch.nsc.ru
Russian Federation, Novosibirsk, 630090
T. V. Abramova
Institute of Chemical Biology and Fundamental Medicine
Author for correspondence.
Email: abramova@niboch.nsc.ru
Russian Federation, Novosibirsk, 630090
Supplementary files
